<code id='6250E24AE7'></code><style id='6250E24AE7'></style>
    • <acronym id='6250E24AE7'></acronym>
      <center id='6250E24AE7'><center id='6250E24AE7'><tfoot id='6250E24AE7'></tfoot></center><abbr id='6250E24AE7'><dir id='6250E24AE7'><tfoot id='6250E24AE7'></tfoot><noframes id='6250E24AE7'>

    • <optgroup id='6250E24AE7'><strike id='6250E24AE7'><sup id='6250E24AE7'></sup></strike><code id='6250E24AE7'></code></optgroup>
        1. <b id='6250E24AE7'><label id='6250E24AE7'><select id='6250E24AE7'><dt id='6250E24AE7'><span id='6250E24AE7'></span></dt></select></label></b><u id='6250E24AE7'></u>
          <i id='6250E24AE7'><strike id='6250E24AE7'><tt id='6250E24AE7'><pre id='6250E24AE7'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:entertainment    Page View:17566
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In